Endocrinology Research Analysis
Q2 2026 endocrinology coalesced around scalable metabolic therapeutics, tissue-resolved mechanisms, and precision diagnostics. Oral small-molecule GLP-1 receptor agonists advanced from phase 3b maintenance (orforglipron) to multicenter phase 2 efficacy (elecoglipron), consolidating a practice-shifting class beyond injectables. Randomized data operationalized difficult care pathways, including semaglutide as pharmacologic rescue after suboptimal bariatric outcomes and fibrosis-stratified cardiohe